TORONTO, July 16, 2020 /CNW/ - Last week, Health
Canada temporarily authorized the adjunctive use of the Dexcom G6
Continuous Glucose Monitoring (CGM) system by pregnant women with
Type 1, Type 2, or gestational diabetes. This temporary expanded
indication was granted because of the active role Dexcom CGM can
play in the treatment and mitigation of COVID-19 by significantly
reducing the in-person interaction between pregnant women with
diabetes and healthcare providers, reducing potential exposure to
the virus.
"The use of Dexcom G6 by pregnant women with diabetes during the
pandemic will allow these women to closely monitor their glucose
levels, complimenting the use of blood glucose meters and
most importantly, enable the remote sharing of glucose data
with their loved ones and caregivers," said Laura Endres, Vice President and General Manager
of Dexcom Canada. "The remote capabilities of Dexcom CGM give
diabetes patients the ability to switch from in-person doctor
visits to telemedicine appointments. This is especially important
during the pandemic, as people with chronic illnesses such as
diabetes are at higher risk for complications related to
COVID-19."
The Dexcom G6 CGM system uses a small, wearable sensor and
transmitter to continuously measure and send glucose levels
wirelessly to a smart device or receiver, * giving those
living with diabetes real-time glucose data †
With customizable alerts and a fixed alarm, the Dexcom G6 CGM
system can remotely share glucose data‡ with loved
ones, with active readings provided every five minutes, day and
night. In addition to providing the user real-time glucose values,
the Dexcom G6 also displays the direction and rate of glucose
change, empowering users to proactively maintain target healthy
glucose levels.
Health Canada's temporary
expanded indication for the adjunctive use of Dexcom G6 by pregnant
women will be in place until March 18,
2021, unless the authorization requires changes within that
timeframe. Health Canada has
updated its website to include a list of the approved CGM systems
along with additional safety statements.
For more information, please review the formal update on the
Health Canada website.
About Dexcom, Inc.
Dexcom, Inc. empowers people to
take control of diabetes through innovative continuous glucose
monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in
Canada, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers and providers, Dexcom simplifies and improves
diabetes management around the world. For more information about
Dexcom CGM, visit www.dexcom.com.
*For a list of compatible devices,
visit www.dexcom.com/compatibility.
†If your glucose alerts and readings from
Dexcom G6 do not match your symptoms or expectations, use a blood
glucose meter to make diabetes treatment decisions.
‡Internet connectivity required for data
sharing. Following requires the use of the Follow App. Followers
should always confirm readings on the Dexcom G6 app or receiver
before making treatment decisions.
© 2020 Dexcom, Inc. Dexcom, Dexcom G6 and Dexcom Follow are
registered trademarks of Dexcom, Inc. in the U.S., and may be
registered in other countries. All rights reserved.
SOURCE Dexcom, Inc.